Samsung Biologics Co Ltd (207940) — Cash Flow Quality Index
Samsung Biologics Co Ltd (207940) has a Cash Flow Quality Index of 1.45x as of June 2026. Operating cash flow of ₩624.80 Billion exceeds net income of ₩430.65 Billion, indicating high earnings quality where cash backs reported profits. Explore Samsung Biologics Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Samsung Biologics Co Ltd Cash Flow Quality Index (2015–2025)
Historical Cash Flow Quality Index for Samsung Biologics Co Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Samsung Biologics Co Ltd operating cash flow efficiency.
Annual Cash Flow Quality Index for Samsung Biologics Co Ltd (2015–2025)
Year-by-year earnings quality comparison for Samsung Biologics Co Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.26x | ₩2.25 Trillion | ₩1.78 Trillion | ▼ -17.8% |
| 2024 | 1.53x | ₩1.66 Trillion | ₩1.08 Trillion | ▼ -13.0% |
| 2023 | 1.76x | ₩1.67 Trillion | ₩945.92 Billion | ▲ +47.5% |
| 2022 | 1.19x | ₩953.05 Billion | ₩798.10 Billion | ▲ +3.4% |
| 2021 | 1.16x | ₩454.60 Billion | ₩393.59 Billion | ▲ +37.7% |
| 2020 | 0.84x | ₩202.09 Billion | ₩240.97 Billion | ▲ +1575.9% |
| 2019 | 0.05x | ₩10.15 Billion | ₩202.90 Billion | ▲ +134.0% |
| 2018 | -0.15x | ₩-33.02 Billion | ₩224.11 Billion | ▼ -6.5% |
| 2015 | -0.14x | ₩-265.51 Billion | ₩1.92 Trillion | — |